These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 18830041)

  • 1. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles].
    Ohta H
    Nihon Rinsho; 2009 May; 67(5):960-6. PubMed ID: 19432117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

  • 5. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
    Iwamoto J
    Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T
    Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
    MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
    [No Abstract]   [Full Text] [Related]  

  • 11. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.
    Lufkin EG; Sarkar S; Kulkarni PM; Ciaccia AV; Siddhanti S; Stock J; Plouffe L
    Curr Med Res Opin; 2004 Mar; 20(3):351-7. PubMed ID: 15025844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM
    Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of SERMs on bone health. Combination therapy with raloxifene].
    Gorai I; Hori H
    Clin Calcium; 2010 Mar; 20(3):408-12. PubMed ID: 20190371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
    Inaba M
    Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
    MMW Fortschr Med; 2003 Jul; 145(27-28):63. PubMed ID: 14587198
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis].
    Matsuo K; Fujinaga M; Tsuchiya K; Nakamoto M; Yasunaga C
    Clin Calcium; 2005 Sep; 15 Suppl 1():92-6; discussion 96-7. PubMed ID: 16272639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of bone quality. Bone quality and osteoporosis treatment].
    Mashiba T
    Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.